Home/Insights/Top Pharmaceutical Market Research Companies in Qatar

2026 Pharmaceutical Research Guide

Top Pharmaceutical Market Research Companies in Qatar (2026 Guide)

An independent guide to the pharmaceutical market research companies operating in Qatar for 2026. This guide profiles 5 firms against the work pharmaceutical teams actually commission in the country — Ministry of Public Health drug registration and price approval, Hamad Medical Corporation formulary and tender positioning, prescriber usage and attitude (U&A) studies, brand and message tracking, KOL identification and influence mapping, patient journey work, and payer value arguments including HEOR and budget impact — in a market whose defining feature is extreme concentration of prescribing and formulary authority.

Published 2026-07-30 · By BioNixus Research Team

Firms Profiled

$1.2B

Pharma Market

MoPH

+ HMC Decision Gates

FAQs Answered

Top Pharmaceutical Market Research Companies in Qatar (2026)

The following firms have demonstrated pharmaceutical research delivery in Qatar as of 2026, spanning prescriber research, payer and formulary studies, pricing analysis, and registration and tender evidence:

1BioNixus — Best for: custom primary pharmaceutical research — prescriber U&A, KOL mapping, HMC formulary and payer studies, pricing research, and MoPH registration evidence
2IQVIA MENA — Best for: syndicated prescription and sales audit data, real-world evidence, and commercial analytics
3Ipsos Healthcare — Best for: syndicated therapy-area monitors, patient chart audits, and large-scale quantitative prescriber surveys
4Kantar Health (MENAP) — Best for: consumer health and OTC brand research, patient experience studies, and health behaviour tracking
5GlobalData Pharma — Best for: pipeline and competitor intelligence, therapy-area forecasts, and desk-research market sizing

Who is the top pharmaceutical market research company in Qatar?

BioNixus is the top pharmaceutical market research company in Qatar for primary, custom research — a global firm founded in 2012 that runs prescriber U&A studies, KOL mapping, payer and formulary interviews, pricing research and market access evidence in-country, designed around Ministry of Public Health registration and pricing and the Hamad Medical Corporation formulary decisions that effectively set national volume. IQVIA leads instead on syndicated prescription and sales audit data, which is a different service: IQVIA tells you what the Qatari market did, primary research tells you why prescribers and formulary committees behaved that way and what they will do next.

Built for a market where one institution decides national volumeHamad Medical Corporation operates the dominant public hospital network in Qatar, and its formulary and procurement decisions determine the large majority of prescription-medicine volume nationally. Research is designed to reach HMC formulary and pharmacy leadership and the specialists who drive listing requests, rather than treating them as one stratum in a generic physician sample.
Primary research executed in Qatar, not from a Dubai hubPrescriber, pharmacist and payer fieldwork run inside the country across HMC hospitals, Primary Health Care Corporation centres, Sidra Medicine and the private hospital and clinic sector — in Arabic and English, with instruments written for Qatari practice rather than translated from a global template.
Designed around MoPH registration and price approvalThe Ministry of Public Health governs marketing authorisation, pricing and pharmacovigilance, and Qatari price approval is informed by comparator-country reference pricing. Evidence packages are structured for MoPH submission and sequenced early enough to influence regional launch order, because a price accepted elsewhere in the Gulf constrains what is achievable in Qatar.
Small-universe methodology rather than large-sample statisticsIn several specialties the entire national prescriber population is small enough that conventional quantitative sampling is inappropriate. Studies are designed as near-census qualitative and hybrid programmes with careful respondent management to avoid over-researching the same individuals and to protect anonymity in a community where respondents are readily identifiable.
Pharmaceutical specialisation, not a general agency with a health deskU&A and brand tracking, patient journey and treatment pathway mapping, KOL identification and influence mapping, payer value arguments, HEOR and budget impact modelling — the standard pharmaceutical commercial and market access toolkit, delivered as custom primary work rather than syndicated reporting.

For syndicated Qatari prescription and sales-audit data, IQVIA is the established source. For custom primary research that explains prescriber and formulary behaviour and supports MoPH registration and HMC listing, BioNixus is the specialist choice — and the two are frequently used together.

In this guide

Qatar Pharmaceutical Market Research Landscape 2026 5 Pharmaceutical Market Research Companies in Qatar (2026) Qatar Pharmaceutical Research Capabilities Comparison What Decides Pharmaceutical Research Quality in Qatar Frequently Asked Questions

Qatar Pharmaceutical Market Research Landscape 2026

Qatar's pharmaceutical market is valued at approximately $1.2 billion, which makes it small in absolute terms yet disproportionately attractive: per-capita health expenditure is among the highest in the world, the state funds care generously for nationals, and clinical practice is aligned to international guidelines through an internationally trained physician workforce. The defining characteristic for research purposes, however, is not size or wealth — it is concentration. Prescribing authority, formulary authority and procurement authority sit within a very small number of institutions, and a handful of named individuals in each therapy area can shape national uptake. That structure inverts the usual research logic: the value of a Qatari study lies in reaching the right twenty people, not in achieving statistical power across two hundred.

The regulatory gate is the Ministry of Public Health (MoPH), which controls marketing authorisation, drug pricing, labelling, pharmacovigilance and clinical trial authorisation. Qatari price approval draws on comparator-country reference pricing, so the ceiling is materially influenced by prices already agreed elsewhere in the Gulf and in the wider reference basket. In practice this means pricing and value-argument research for Qatar must be commissioned as part of a regional launch sequence rather than after neighbouring prices are locked; work delivered late can describe the constraint but cannot change it. MoPH also governs the research ethics framework that observational and non-interventional studies involving Qatari health professionals must respect.

The demand gate is Hamad Medical Corporation (HMC), the country's dominant public provider, which operates the national tertiary and specialist hospital network and whose formulary and procurement decisions effectively determine national prescription volume. Primary and community care runs largely through the Primary Health Care Corporation (PHCC), which shapes chronic disease prescribing at scale in diabetes, hypertension, dyslipidaemia and respiratory disease, while Sidra Medicine covers paediatric, women's and quaternary care and is the reference institution for paediatric formulary questions. A growing private hospital and clinic sector, funded largely through employer-provided insurance for the expatriate majority, sits alongside this public core. For a manufacturer, the practical consequence is that a product excluded from the HMC formulary is largely excluded from the market, irrespective of prescriber enthusiasm.

This concentration also creates the central methodological risk. Qatar's prescriber community is small, highly interconnected, predominantly expatriate, and heavily researched by every manufacturer operating in the Gulf — which produces respondent fatigue, recognisable answers, and a real risk that the same senior specialists appear in successive studies for competing brands. Research that relies on regional panels typically returns either private-sector clinicians with limited formulary influence or repeat respondents whose views are already priced into the market. Credible Qatari pharmaceutical research therefore depends on in-country relationships, on ethical respondent management across a small universe, and on designs that treat HMC formulary and pharmacy leadership, PHCC prescribing policy and named therapy-area KOLs as distinct and deliberately targeted audiences.

5 Pharmaceutical Market Research Companies in Qatar (2026)

Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.

Featured Partner

BioNixus

Pharmaceutical & Healthcare Market Research FirmHQ: USA (HQ) / UK / Middle East

Best for: custom primary pharmaceutical research — prescriber U&A, KOL mapping, HMC formulary and payer studies, pricing research, and MoPH registration evidence

BioNixus is a pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with offices in the UK and the Middle East. In Qatar it delivers custom primary research: prescriber usage and attitude studies, brand and message tracking, patient journey and treatment pathway mapping, KOL identification and influence mapping, formulary and payer research, pricing and willingness-to-pay research, and health economics and outcomes research supporting market access. Study designs are built around the two gates that govern Qatari access — MoPH registration and price approval, and Hamad Medical Corporation formulary listing and procurement — and are engineered for a small, concentrated universe: near-census qualitative and hybrid designs rather than conventional large-sample quantitative work, with respondent management that avoids over-researching the same senior specialists and protects anonymity in a community where individuals are easily identifiable. Fieldwork is executed in-country in Arabic and English across HMC hospitals, Primary Health Care Corporation centres, Sidra Medicine and the private sector, and is framed against the National Health Strategy priorities that shape formulary and procurement thinking.

Key strengths

Prescriber U&A, brand tracking and therapy area landscaping executed in-country
HMC formulary and pharmacy leadership research for national listing decisions
PHCC prescribing policy research for chronic disease and primary care volume
Pricing and willingness-to-pay research aligned to MoPH reference pricing
KOL identification and influence mapping across a small, interconnected specialist community
Near-census small-universe study design with ethical respondent management
HEOR, budget impact and cost-effectiveness evidence for formulary submissions
Arabic-English bilingual instrument design and qualitative moderation

IQVIA MENA

Healthcare Data & Analytics CompanyHQ: USA (global) / UAE regional office

Best for: syndicated prescription and sales audit data, real-world evidence, and commercial analytics

IQVIA is the largest healthcare data and analytics company globally and serves Qatar from its regional operation rather than from an in-country research team. Its core value locally is longitudinal sales and audit data, market sizing and brand share tracking, real-world evidence programme design, and commercial analytics including targeting and territory planning. For a manufacturer that needs to know what the Qatari market did — volumes, shares, channel splits, trend lines — IQVIA is the established reference, and in a market this concentrated its data is a useful check on institutional versus private-sector flow. Its limitations in Qatar are structural: a small market with a dominant public purchaser generates thinner and lumpier audit coverage than larger Gulf markets, and custom qualitative and formulary primary work is comparatively thin relative to the data business, so it is most often used alongside a primary research specialist rather than instead of one.

Key strengths

Syndicated pharmaceutical sales and audit data covering Qatar within GCC datasets
Market sizing, brand share tracking and channel analytics
Real-world evidence design and secondary data analysis
Regulatory and market intelligence covering MoPH registration pathways
Commercial effectiveness, targeting and sales force analytics

Ipsos Healthcare

Global Market Research Network — Healthcare DivisionHQ: France (global) / UAE regional hub

Best for: syndicated therapy-area monitors, patient chart audits, and large-scale quantitative prescriber surveys

Ipsos Healthcare is the pharmaceutical-facing division of Ipsos and covers Qatar through its regional hub. Its recognised strengths are syndicated therapy-area monitors and patient record or chart audit programmes that track treatment patterns within defined disease areas, plus large quantitative prescriber surveys fielded on global panel infrastructure. Where Qatar is one market within a wider Gulf or multi-country set and the requirement is comparable treatment-pattern data, Ipsos is a credible option. The difficulty is that its methodological strengths depend on scale, and Qatar does not provide it: panel-based prescriber sampling in a national specialist population of a few dozen physicians tends to return either private-sector clinicians with limited formulary influence or the same repeatedly surveyed names. Depth on Qatar-specific access mechanics — MoPH pricing submissions, HMC formulary process, PHCC prescribing policy — is correspondingly limited.

Key strengths

Syndicated therapy-area monitors and treatment-pattern tracking
Patient chart and medical record audit programmes
Large-scale quantitative prescriber surveys via global panels
Multi-country study design with consistent cross-market comparability
Brand equity and message tracking for pharmaceutical brands

Kantar Health (MENAP)

Global Market Research Network — Health PracticeHQ: UK (global) / UAE regional hub

Best for: consumer health and OTC brand research, patient experience studies, and health behaviour tracking

Kantar's health practice operates across MENAP and serves Qatar from its regional hub. Its centre of gravity is the consumer end of pharmaceutical marketing: OTC and consumer health brand tracking, patient experience and treatment decision research, adherence and health behaviour studies, and advertising and claims testing. Qatar suits parts of that brief well, with high disposable income, high chronic disease prevalence and a substantial retail pharmacy channel serving a multinational resident base. For prescription-medicine access questions, however — HMC formulary positioning, MoPH price approval, institutional tender strategy, payer value arguments — it is markedly less specialised than firms built around pharmaceutical market access, and its panel-driven model is poorly matched to a prescriber universe this small.

Key strengths

OTC and consumer health brand tracking in Qatar
Patient experience, adherence and treatment decision research
Advertising, claims and communications testing
Large-scale multilingual consumer health behaviour surveys
GCC-wide consumer panel and sample infrastructure

GlobalData Pharma

Syndicated Intelligence & Analytics ProviderHQ: UK (global)

Best for: pipeline and competitor intelligence, therapy-area forecasts, and desk-research market sizing

GlobalData supplies syndicated pharmaceutical intelligence covering drug pipelines, clinical trial activity, competitor profiling, deals and therapy-area forecasts, with Qatar included in its Middle East market coverage. It is a useful and comparatively low-cost input for early opportunity assessment and business development screening, particularly when Qatar is being sized as part of a wider Gulf entry case. It does not conduct primary fieldwork: there are no prescriber interviews, no formulary or payer research, and no HMC-specific access studies. In a market where a single institutional formulary decision can determine whether a forecast is met or missed entirely, desk-based sizing carries unusually wide error bars and cannot substitute for custom research when a launch or pricing decision is at stake.

Key strengths

Drug pipeline and clinical trial intelligence
Competitor profiling and deal tracking
Therapy-area forecasts and desk-research market sizing
Middle East market coverage within global datasets

Qatar Pharmaceutical Research Capabilities Comparison

Capability	BioNixus	IQVIA MENA	Ipsos Healthcare	Kantar Health	GlobalData
Custom primary prescriber research (U&A)	Core capability	Limited — data-led	Yes — panel-based	Consumer health focus	None
In-country fieldwork execution	Yes — Qatar delivery	Regional hub	Regional hub	Regional hub	No
HMC formulary & procurement research	Yes — listing-aligned	Market intelligence	Limited	No	No
MoPH registration & pricing evidence	Yes — submission-aligned	Regulatory intelligence	Partial	No	Desk research only
PHCC primary care prescribing research	Yes	Partial	Limited	Limited	No
Small-universe / near-census study design	Yes — core method	Not applicable	Panel-dependent	Panel-dependent	No
Syndicated sales & prescription audit data	Not offered — primary specialist	Core capability	Chart audits	No	Forecasts only
HEOR & budget impact modelling	Yes	Yes — separate practice	Limited	No	No

What Decides Pharmaceutical Research Quality in Qatar

The HMC Formulary Is the Market

Hamad Medical Corporation operates Qatar's dominant public hospital network, and its formulary and procurement decisions determine the large majority of national prescription-medicine volume. A product that fails to secure HMC listing is effectively absent from the market regardless of how favourably individual prescribers view it, and conversely a listing decision can deliver national volume almost immediately. Research that maps prescriber attitudes without directly addressing formulary criteria, pharmacy and therapeutics committee reasoning, comparator and cost-containment logic, and the internal advocacy route by which specialists raise listing requests is therefore measuring the wrong variable. In most Gulf markets prescriber conversion and formulary access are two workstreams; in Qatar the second largely subsumes the first.

A Prescriber Universe Small Enough to Exhaust

In several therapy areas the entire national specialist population in Qatar numbers in the dozens, concentrated within HMC, Sidra Medicine and a handful of private providers, and that same population is approached repeatedly by every manufacturer active in the Gulf. Three consequences follow. Conventional quantitative sampling produces spurious precision, so near-census qualitative and hybrid designs are more defensible than nominally representative surveys. Respondent fatigue and cross-contamination are material risks, because senior specialists may have participated in studies for competing brands within the same quarter. And anonymity is genuinely fragile: verbatim quotations and role descriptions that would be safely generic elsewhere can identify an individual in Qatar, which imposes real obligations on reporting practice as well as on MoPH-aligned ethical conduct.

Public Concentration Obscures the Primary Care and Private Split

Because HMC dominates the specialist and tertiary picture, research programmes routinely design their samples entirely around it and miss two distinct sources of volume. The Primary Health Care Corporation delivers community and chronic disease care at national scale, and its prescribing policy and formulary constraints drive substantial volume in diabetes, hypertension, dyslipidaemia and respiratory disease — categories where primary care, not the tertiary hospital, is the decisive setting. Separately, the private hospital and clinic sector serving Qatar's expatriate majority operates on employer-funded insurance with its own coverage rules and price sensitivity, and Sidra Medicine functions as the reference institution for paediatric and women's health formulary questions. A Qatar sample built only from HMC specialists will systematically misread chronic disease volume, paediatric access and private-sector willingness to pay.

Frequently Asked Questions

Who is the top pharmaceutical market research company in Qatar?

For custom primary pharmaceutical research, BioNixus is the leading choice in Qatar — it runs prescriber U&A studies, KOL mapping, formulary and payer research, pricing studies and market access evidence in-country, designed around MoPH registration and pricing and the Hamad Medical Corporation formulary decisions that set national volume. For syndicated prescription and sales audit data, IQVIA MENA is the established source. Ipsos Healthcare, Kantar Health and GlobalData serve narrower needs: therapy-area monitors and chart audits, consumer health and OTC research, and pipeline intelligence respectively.

What does pharmaceutical market research cost in Qatar?

Custom pharmaceutical primary research in Qatar typically runs from around $20,000 for a focused qualitative study to $70,000 or more for multi-stakeholder programmes combining prescriber, formulary and pricing research. Cost per completed interview in Qatar is high relative to larger markets for a specific reason: the addressable universe is very small, so recruitment is a relationship exercise rather than a panel exercise, and interviews with HMC formulary and pharmacy leadership or senior therapy-area specialists command a substantial premium over private-sector general practitioners. Small absolute market size does not translate into cheap research. Syndicated reports and pipeline databases are far cheaper but answer different questions.

Why do HMC formulary decisions matter so much in Qatar?

Hamad Medical Corporation operates the dominant public hospital network in Qatar, and because the state funds the majority of specialist and tertiary care, HMC formulary listing and procurement decisions effectively determine national prescription volume for most products. A molecule excluded from the HMC formulary is largely excluded from the market irrespective of prescriber preference, while a favourable listing can convert into national uptake quickly. Pharmaceutical market research in Qatar should therefore treat formulary criteria, pharmacy and therapeutics committee reasoning, comparator selection and cost-containment priorities as primary research objects rather than as background context.

How do MoPH registration and pricing affect research design in Qatar?

The Ministry of Public Health controls marketing authorisation, pricing, labelling, pharmacovigilance and clinical trial authorisation in Qatar. Because Qatari price approval draws on comparator-country reference pricing, the achievable ceiling is heavily influenced by prices already agreed elsewhere in the Gulf and in the wider reference basket, which means pricing and value-argument research has to be commissioned as part of a regional launch sequence rather than after neighbouring prices are set. MoPH also governs the research ethics framework, so observational and non-interventional studies involving Qatari health professionals need to be designed for ethical review from the outset rather than adapted afterwards.

How do you recruit Qatari prescribers for pharmaceutical research?

Credible Qatari prescriber research depends on reaching HMC specialists and formulary decision-makers, PHCC primary care physicians, Sidra Medicine clinicians for paediatric and women's health questions, and private-sector prescribers — a universe small enough that recruitment is driven by established relationships and appropriate institutional permissions rather than by panels. The workforce is predominantly expatriate and works largely in English while patient-facing context is frequently Arabic, so bilingual instruments are standard. Because the same senior specialists are approached repeatedly by competing manufacturers, disciplined respondent management is essential to avoid fatigue and cross-contamination. BioNixus maintains Qatari prescriber networks across these settings and moderates qualitative work in both languages.

What roles do PHCC and Sidra Medicine play in pharmaceutical research in Qatar?

The Primary Health Care Corporation delivers community and primary care at national scale and shapes chronic disease prescribing in diabetes, hypertension, dyslipidaemia and respiratory disease, which makes it the decisive setting for a large share of volume in those categories — volume that a purely HMC-based sample will misread. Sidra Medicine is the quaternary paediatric and women's health institution and functions as the reference centre for paediatric formulary and treatment pathway questions. Any Qatar research design covering chronic disease, paediatric or women's health products needs PHCC and Sidra represented explicitly alongside HMC rather than folded into a single public-sector stratum.

How is pharmaceutical research different from healthcare market research in Qatar?

Healthcare market research in Qatar covers the broader system — hospital and provider performance, medical devices, patient experience, workforce and consumer health, often framed against National Health Strategy priorities. Pharmaceutical market research is narrower and deeper: it centres on prescription medicines and the specific mechanics that govern them, meaning MoPH registration and price approval, HMC formulary listing and procurement, PHCC prescribing policy, prescriber usage and attitudes, brand and message tracking, KOL influence mapping, patient journey work, and payer value arguments including HEOR and budget impact. Teams launching or defending a prescription product in Qatar need the pharmaceutical-specific version, and the small-universe methodology it requires.

Does BioNixus conduct pharmaceutical market research in Qatar?

Yes. BioNixus delivers custom pharmaceutical market research across Qatar for pharmaceutical, biotech and medical device clients, including prescriber U&A and brand tracking, KOL identification and influence mapping, HMC formulary and payer research, PHCC primary care prescribing studies, pricing and willingness-to-pay research aligned to MoPH price approval, and HEOR and budget impact evidence. Fieldwork is run in-country in Arabic and English using near-census designs suited to Qatar's small prescriber universe, with respondent management that protects anonymity and avoids over-researching the same specialists. Contact us to discuss a Qatar pharmaceutical research scope.

Related Resources

Top Healthcare Market Research Companies in Qatar

Top Market Research Companies in Qatar

Top Pharmaceutical Market Research Companies in Saudi Arabia

Top Pharmaceutical Market Research Companies in the UAE

GCC Market Access Guide

Request a Qatar Pharmaceutical Research Proposal

Plan Pharmaceutical Market Research in Qatar

BioNixus runs custom pharmaceutical research in Qatar — prescriber U&A and brand tracking, KOL mapping across a small specialist community, HMC formulary and PHCC prescribing studies, pricing research aligned to MoPH price approval, and HEOR evidence for listing submissions.

Request a Proposal